Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07264517 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
A Phase 2 study of Dry Eye Disease, sponsored by Instituto Grifols, S.A..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 10
- Study locations
NCT07264517: Recruiting Phase 2 study of Dry Eye Disease, sponsored by Instituto Grifols, S.A..
NCT07264517 is a Phase 2 study of Dry Eye Disease that is actively recruiting participants, run by Instituto Grifols, S.A.. The registered enrollment target is 100 participants, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (60% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07264517, a Phase 2 study of Dry Eye Disease, is actively recruiting participants, sponsored by Instituto Grifols, S.A..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
Conditions Studied
Interventions
- DRUG GRF312 5%
- OTHER Placebo Comparator
Study Locations (10)
California
- GC2302 Study Site 110 - Glendale
- GC2302 Study Site 109 - Grove
- GC2302 Study Site 103 - Newport Beach
North Carolina
- GC2302 Study Site 104 - Asheville
- GC2302 Study Site 101 - Garner
Georgia
- GC2302 Study Site 105 - Morrow
Indiana
- GC2302 Study Site 106 - Carmel
Pennsylvania
- GC2302 Study Site 107 - Cranberry Township
Tennessee
- GC2302 Study Site 102 - Memphis
Texas
- GC2302 Study Site 111 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2026-11-14 |
| Phase | Phase 2 |
What NCT07264517 shows while recruiting
NCT07264517 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which GRF312 5% is the first listed.
NCT07264517 lists 10 locations in 7 states (California, North Carolina, Georgia).
Frequently Asked Questions
What is clinical trial NCT07264517 about?
NCT07264517 is a clinical study titled "Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).". This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
What is the current status of trial NCT07264517?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-11-03. Estimated completion is 2026-11-14.
What conditions does trial NCT07264517 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT07264517?
The interventions under investigation include: GRF312 5% (DRUG), Placebo Comparator (OTHER).
Who is sponsoring clinical trial NCT07264517?
This trial is sponsored by Instituto Grifols, S.A., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07264517 being conducted?
This trial has 10 study locations across California, Georgia, Indiana, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07264517's enrollment target sits among peer trials
100 22nd of 33 higher than 11 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
COMPLETED · Phase 2
-
A Study of TL-925 as a Treatment for Dry Eye Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI